Literature DB >> 28185388

Characteristics of extracellular cyclic AMP-dependent protein kinase as a biomarker of cancer in dogs.

D H Bhang1, U S Choi2, B G Kim1, S-N Lee1, S Lee1, H-S Roh1, W-J Chung3, K O Jeon4, W J Song4, H-Y Youn4, K-H Baek1.   

Abstract

OBJECTIVE: Early and proper diagnosis of cancer is the most critical factor for the survival and treatment of veterinary cancer patients. In this study, we evaluated extracellular cyclic AMP-dependent protein kinase A (ECPKA) level in serum as a useful cancer biomarker in dogs.
METHODS: ECPKA levels were detected in sera from dogs with cancers (n = 48), benign tumours (n = 18), and non-tumour diseases (n = 102) as well as healthy control dogs (n = 54) utilizing enzyme-linked immunosorbent assay (ELISA).
RESULTS: Sera from dogs bearing various types of cancer exhibited markedly increased levels of ECPKA by up to 7.1-, 8.8-, and 10.9-fold compared with those from dogs harbouring benign tumours, dogs with non-tumour diseases, and healthy control dogs, respectively (P < .0001). In addition, serum ECPKA level did not show statistically significant correlation with gender, breed, or age of dogs or their non-cancerous disease conditions.
CONCLUSION: Our data strongly propose that detection of serum ECPKA level is a potential and specific diagnostic tool for cancer in dogs.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer biomarker; dog; enzyme-linked immunosorbent assay; extracellular protein kinase A; serum

Mesh:

Substances:

Year:  2017        PMID: 28185388     DOI: 10.1111/vco.12304

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  2 in total

1.  AniScan Using Extracellular Cyclic AMP-Dependent Protein Kinase A as a Serum Biomarker Assay for the Diagnosis of Malignant Tumors in Dogs.

Authors:  Ji-Eun Lee; Woo-Jin Song; Hunjoo Lee; Byung-Gak Kim; Taeho Kim; Changsun Lee; Bonghwan Jang; Hwa-Young Youn; Ul-Soo Choi; Dong-Ha Bhang
Journal:  Sensors (Basel)       Date:  2020-07-22       Impact factor: 3.576

Review 2.  Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity.

Authors:  Dominique R Perez; Larry A Sklar; Alexandre Chigaev; Ksenia Matlawska-Wasowska
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.